“Convergence science has advanced across many fronts, from nanotechnology to regenerative tissue,” says Nobel Laureate Phil Sharp of MIT. “But the funding allocated for convergence research in biomedical science is small and needs to be expanded. In fact, there is no federal agency with the responsibility to fund convergence in biomedical research.”
Four Boston area Israeli collaborations receive $1.3 in funding for innovative medical and energy projects under new MA/Israel partnership.
AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech,of the Roche Group, for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. The agreement is valued at $400M.
Writer-content strategist Anita Harris describes a recent panel discussion in which she, Stephen Smith of the Boston Globe and Lara Salahi of ABC News spoke to Emerson College students about careers in health communications.
I asked when and how these groundbreaking technologies will affect the costs and structure of US healthcare–and whether those who make and market our costly technologies will try to keep these new testing devices from our marketplace.